Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer

Czech version

Authors: K. Kubáčková
Authors‘ workplace: Onkologická klinika 2. LF UK a FN v Motole, Praha
Published in: Klin Onkol 2015; 28(Supplementum 4): 69-72
Category: Specials
doi: https://doi.org/10.14735/amko20154S69

Overview

In recent years, thanks to new advances in tumor immunology, immunotherapy became a part of intensive research as a novel strategy in cancer treatment. Sipuleucel‑ T is the first and only medicinal product approved by the regulatory agencies in the USA and Europe for the treatment of asymptomatic or minimal symptomatic castrate‑ refractory prostate cancer. It represents the first product of autologous cell therapy. This article gives a brief overview of new approaches in cancer immunotherapy in clinical development.

Key words:
prostate cancer – cancer immunity – immunotherapy – anticancer vaccines

This article was supported by the project (of Ministry of Health) of conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203.

The author declares conflicts of interest for Sotio (investigator).

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
18. 8. 2015

Accepted:
16. 9. 2015

Sources

1. Coulie PG, Van den Eynde BJ, van der Bruggen P et al. Tumor antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Clin Oncol 2014; 14(2): 135– 146.

2. Krysko DV, Garg AD, Kaczmarek A et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Clin Oncol 2012; 12(12): 860– 862. doi: 10.1038/ nrc3380.

3. McNeel DG, Smith HA, Eickhoff JC et al. Phase I trial of tremelimumab in combination with short‑term androgen deprivation in patiens with PSA‑ recurrent prostate cancer. Cancer Immunol Immunother 2012; 61(7): 1137– 1147. doi: 10.1007/ s00262‑ 011‑ 1193‑ 1.

4. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and aktivity od anti‑PD‑ L1 antibody in patiens with advanced cancer. N Engl J Med 2012; 366(26): 2455– 2465. doi: 10.1056/ NEJMoa1200694.

5. Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013; 15(2): 98– 104. doi: 10.1007/ s11912‑ 012‑ 0284‑ 2.

6. Ogino S, Galon J, Fuchs CS et al. Cancer immunology – analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011; 8(12): 711– 719. doi: 10.1038/ nrclinonc.2011.122.

7. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy dones of age. Nat Rev Clin Oncol 2011; 480(7378): 480– 489. doi: 10.1038/ nature10673.

8. Burch PA, Breen JK, Buckner JC et al. Primary tissue‑ specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6(6): 2175– 2182.

9. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel‑ T immunotherapy foro castration‑resistant prostate cancer. N Engl J Med 2010; 363(5): 411– 422. doi: 10.1056/ NEJMoa1001294.

10. Sheikh NA, Petrylak D, Kantoff PW et al. Sipuleucel‑ T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration‑resistant prostate cancer. Cancer Immunol Immunother 2013; 62(1): 137– 147. doi: 10.1007/ s00262‑ 012‑ 1317‑ 2.

11. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102(18): 1388– 1397. doi: 10.1093/ jnci/ djq310.

12. Fong L, Weinberg V, Chan SE et al. Neoadjuvant sipuleucel‑ T in localized prostate cancer: effects on immune cells within the prostate tumor microenvironment (abstract 2564) . ASCO annual meeting abstracts. Accesed September 10, 2013.

13. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral‑based PSA‑ targeted immunotherapy in metastatic castration‑resistant prostate cancer. J Clin Oncol 2010; 28(7): 1099– 1105. doi: 10.1200/ JCO.2009.25.0597.

14. Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral‑based PSA vaccine in metastatic castrate‑resistant prostate cancer. Cancer Immunol Immunother 2010; 59(5): 663– 674. doi: 10.1007/ s00262‑ 009‑ 0782‑ 8.

15. Small EJ, Reese DM, Um B et al. Therapy of advanced prostate cancer with granulocyte macrophage colony‑ stimulating factor. Clin Cancer Res 1999; 5(7): 1738– 1744.

16. Higano C, Saad F, Somer B et al. A phase III trial od GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic, castration‑resistant prostate cancer (CRPC) (abstract LBA150) . Presented at the Genitourinary Cancers Symposium. Orlando, Florida, February 26– 28, 2009.

17. Cheng ML, Fong L. Beyond sipuleucel‑ T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 2014; 15(1): 115– 126. doi: 10.1007/ s11864‑ 013‑ 0267‑ z.

18. Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014; 33(2– 3): 641– 655. doi: 10.1007/ s10555‑ 013‑ 9479‑ 8.

19. Podrazil M, Horvath R, Becht E et al. Phase I/ II trial of dendritic‑ cell based immunotherapy (DCVAC/ PCa) combined with chemotherapy in patiens with metastatic, castration‑resistant prostate cancer. Oncotarget 2015; 6(20): 18192– 18205.